Amit Kumar, Chief Executive Officer at Anixa Biosciences Inc (ANIX), bought 5,000 shares at $3.04 ($15K) on 2026-07-10, disclosed to the SEC on 2026-07-13.
CEO Amit Kumar purchased 5,000 shares for $15,200 on July 10, 2026, marking the largest insider purchase in Anixa Biosciences' history. This significant buyback by the CEO suggests confidence in the company's pipeline and recent operational progress.
The stock is up 25.31% over the last 30 days to $3.07, though it remains 43.74% below its 52-week high of $5.46.
Catalysts include the Korean patent secured on June 30, 2026, for the breast cancer vaccine, and the Phase II vaccine plan outlined at the April 15, 2026, conference. Additionally, CEO Amit Kumar designated 2026 as a 'pivotal year' in February 2026 for advancing clinical programs.
The stock carries a short interest of 2.75% of the float, and the company trades at a negative forward P/E of -9.87, indicating ongoing losses.
Nothing distinguishes this filing.
| Filing → |
| ANIX | BUY | 2026-09-11 | $14K | — | Filing → |
| ANIX | BUY | 2026-08-03 | $17K | — | Filing → |
| ANIX | BUY | 2026-07-28 | $17K | — | Filing → |